Form 4: NewAmsterdam Pharma Co N.V. Executive Acquires Shares and Options

Johannes Jacob Pieter Kastelein, Chief Scientific Officer of NewAmsterdam Pharma Co N.V., reports acquisition of shares and options.

Summary

• Johannes Jacob Pieter Kastelein, the Chief Scientific Officer of NewAmsterdam Pharma Co N.V., has reported changes in beneficial ownership.
• On March 24, 2025, Kastelein acquired 150,000 ordinary shares through the exercise of options.
• These shares are held indirectly through Futurum B.V., over which Kastelein exercises sole voting and investment control.
• Kastelein also holds options for 820,229 ordinary shares indirectly through Futurum via NAP PoolCo B.V.
• The option exercised had a price of 1.16392 Euros.
• The exercised option was granted on November 22, 2022, replacing an option from July 6, 2021, and vested over time subject to continued service.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing insider transactions. The acquisition of shares could be interpreted slightly positively, but it's not a strong indicator.

Positives

• The acquisition of shares by a key executive could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's securities.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• Similar filings are common among pharmaceutical companies like Amgen, Pfizer, and Novartis, when their executives trade company stock.

Stakeholder Impact

• Shareholders may view the insider's stock acquisition as a positive sign of confidence in the company's prospects.

Key Dates

Keywords

NewAmsterdam Pharma, Kastelein, Insider Trading, Beneficial Ownership, Form 4, Options, Shares, NAMS